Blueprint Medi Cm ST (BPMC) 29.17 $BPMC Bluepri
Post# of 273254
Posted On: 09/21/2016 5:01:18 PM
Blueprint Medi Cm ST (BPMC) 29.17 $BPMC
Blueprint Medicines Announces New Drug Discovery Program Targeting PRKACA Kinase Fusions for the Treatment of Fibrolamellar Carcinoma at 10th International Liver Cancer Association (ILCA) Annual Conference
PR Newswire - Fri Sep 09, 7:30AM CDT
Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today disclosed a new drug discovery program targeting protein kinase cAMP-activated catalytic subunit alpha (PRKACA) fusions for the treatment of fibrolamellar carcinoma (FLC). The announcement was made during an oral presentation on September 8, 2016 at the 10th ILCA Annual Conference in Vancouver, Canada on Blueprint Medicines' efforts to develop targeted therapies for patients with hepatocellular carcinoma.
BPMC: 29.17 (-0.10)
Blueprint Medicines to Present at Morgan Stanley Global Healthcare Conference
PR Newswire - Wed Sep 07, 7:30AM CDT
Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today announced that Jeff Albers, Blueprint Medicines' Chief Executive Officer, will present a company overview at the Morgan Stanley Global Healthcare Conference on Wednesday, September 14, 2016 at 11:40 a.m. ET.
BPMC: 29.17 (-0.10), MS: 31.92 (+0.22)
Blueprint Medicines Announces Appointment of Tracey McCain as Chief Legal Officer and Executive Vice President
PR Newswire - Tue Sep 06, 3:01PM CDT
Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective investigational kinase medicines for patients with genomically defined diseases, today announced the appointment of Tracey McCain as Chief Legal Officer and Executive Vice President. Ms. McCain will be a member of the executive management team and will be responsible for all corporate legal operations for Blueprint Medicines.
BPMC: 29.17 (-0.10)
Why Blueprint Medicines (BPMC) Stock Might be a Great Pick
Zacks Equity Research - Zacks Investment Research - Tue Aug 16, 9:21AM CDT
Blueprint Medicines (BPMC) looks like an interesting choice for investors, as it is seeing solid estimate revisions and belongs to a great industry.
BPMC: 29.17 (-0.10)
Blueprint Medicines Reports Second Quarter 2016 Financial Results
PR Newswire - Tue Aug 09, 6:00AM CDT
Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today reported financial results and provided a business update for the second quarter ended June 30, 2016.
BPMC: 29.17 (-0.10)
Blueprint Medicines to Present at Upcoming Investor Conferences in August
PR Newswire - Wed Aug 03, 7:00AM CDT
Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today announced its participation in the following upcoming investor conferences:
BPMC: 29.17 (-0.10)
Blueprint Medicines to Report Second Quarter 2016 Financial Results on Tuesday, August 9, 2016
PR Newswire - Tue Aug 02, 7:00AM CDT
Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today announced that it will report second quarter 2016 financial results on Tuesday, August 9, 2016. Blueprint Medicines' management team will host a live conference call and audio webcast at 8:30 a.m. EDT on Tuesday, August 9, 2016 to discuss the financial results and provide a corporate update.
BPMC: 29.17 (-0.10)
Blueprint Medicines to Present at Upcoming Investor Conferences in June
PR Newswire - Wed Jun 01, 3:05PM CDT
Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today announced its participation in the following upcoming investor conferences:
BPMC: 29.17 (-0.10)
Blueprint Medicines reports 1Q loss
Automated Insights - Tue May 10, 6:26AM CDT
CAMBRIDGE, Mass. (AP) _ Blueprint Medicines Corp. (BPMC) on Tuesday reported a loss of $15.5 million in its first quarter.
BPMC: 29.17 (-0.10)
Blueprint Medicines Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 10, 6:00AM CDT
Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today reported financial results and provided a business update for the first quarter ended March 31, 2016.
BPMC: 29.17 (-0.10)
Blueprint Medicines to Report First Quarter 2016 Financial Results on Tuesday, May 10, 2016
PR Newswire - Tue May 03, 7:00AM CDT
Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today announced that it will report first quarter 2016 financial results on Tuesday, May 10, 2016. Blueprint Medicines' management team will host a live conference call and audio webcast at 8:00 a.m. EDT on Tuesday, May 10, 2016 to discuss the financial results and provide a corporate update.
BPMC: 29.17 (-0.10)
New Strong Buy Stocks for April 25th
Zacks Equity Research - Zacks Investment Research - Mon Apr 25, 8:15AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
BPMC: 29.17 (-0.10), BV: 5.00 (unch), ALGN: 95.34 (+1.64), BNFT: 38.43 (+0.65), BECN: 41.03 (+1.50)
Blueprint Medicines Appoints Lynn Seely, M.D. to Board of Directors
PR Newswire - Fri Apr 15, 7:00AM CDT
Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today announced the appointment of Lynn Seely, M.D. to its board of directors. Dr. Seely brings more than 20 years of cross-functional expertise within the healthcare industry, including experience in clinical and product development, business development and regulatory affairs.
BPMC: 29.17 (-0.10)
Global Liver Cancer Pipeline Review, H2 2015 - 150+ Companies & Drug Profiles
M2 - Tue Feb 09, 8:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/5j6swm/liver_cancer) has announced the addition of the "Liver Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Liver CancerOverview - Therapeutics Development - Pipeline Products for Liver Cancer- Overview - Pipeline Products for Liver Cancer- Comparative Analysis - Liver Cancer- Therapeutics under Development by Companies - Liver Cancer- Therapeutics under Investigation by Universities/Institutes - Liver Cancer- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Liver Cancer- Products under Development by Companies - Liver Cancer- Products under Investigation by Universities/Institutes - Liver Cancer- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 4SC AG - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - ACROVIS Pharma AG - Adaptimmune Limited - Aduro BioTech, Inc. - Advanced Accelerator Applications SA - Advenchen Laboratories, LLC - Alfact Innovation - Alnylam Pharmaceuticals, Inc. - American Gene Technologies International Inc. - Amgen Inc. - AndroScience Corporation - APAvadis Biotechnologies Srl - Arbutus Biopharma Corporation - ArQule, Inc. - Array BioPharma Inc. - Arrowhead Research Corporation - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bayer AG - Bio-Cancer Treatment International Limited - BioCancell Ltd - Biogazelle - Bioneer Corporation - BioStar Pharmaceuticals, Inc. - Blueprint Medicines - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - CASI Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/5j...ver_cancer
BPMC: 29.17 (-0.10), BSPM: 3.80 (unch), ADRO: 14.68 (+0.15), ARWR: 7.21 (-0.15), ARQL: 1.62 (+0.02), AMGN: 173.85 (+0.47), CASI: 1.05 (-0.02), BMY: 55.93 (+0.37), CLBS: 4.75 (+0.06), AAAP: 38.42 (-0.11), CANF: 2.62 (+0.10), ABUS: 3.89 (+0.05), AZN: 33.75 (+0.10), AVEO: 0.87 (unch), ABBV: 64.10 (+0.82), XLRN: 38.12 (+0.64), ARRY: 3.59 (-0.05)
Blueprint Medicines hires Lonnel Coats to board
M2 - Fri Feb 05, 3:01AM CST
Kinase medicines company Blueprint Medicines (NasdaqGS:BPMC) disclosed on Thursday the election of Lonnel Coats to its board of directors.
BPMC: 29.17 (-0.10), LXRX: 18.90 (-0.34)
Blueprint Medicines Appoints Lonnel Coats to Board of Directors
PR Newswire - Thu Feb 04, 3:05PM CST
Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective investigational kinase medicines for patients with genomically defined diseases, today announced the appointment to its board of directors of Lonnel Coats, a seasoned pharmaceutical executive with nearly 30 years of industry-related experience.
BPMC: 29.17 (-0.10), LXRX: 18.90 (-0.34)
Blueprint Medicines Announces New Drug Discovery Program Targeting PRKACA Kinase Fusions for the Treatment of Fibrolamellar Carcinoma at 10th International Liver Cancer Association (ILCA) Annual Conference
PR Newswire - Fri Sep 09, 7:30AM CDT
Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today disclosed a new drug discovery program targeting protein kinase cAMP-activated catalytic subunit alpha (PRKACA) fusions for the treatment of fibrolamellar carcinoma (FLC). The announcement was made during an oral presentation on September 8, 2016 at the 10th ILCA Annual Conference in Vancouver, Canada on Blueprint Medicines' efforts to develop targeted therapies for patients with hepatocellular carcinoma.
BPMC: 29.17 (-0.10)
Blueprint Medicines to Present at Morgan Stanley Global Healthcare Conference
PR Newswire - Wed Sep 07, 7:30AM CDT
Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today announced that Jeff Albers, Blueprint Medicines' Chief Executive Officer, will present a company overview at the Morgan Stanley Global Healthcare Conference on Wednesday, September 14, 2016 at 11:40 a.m. ET.
BPMC: 29.17 (-0.10), MS: 31.92 (+0.22)
Blueprint Medicines Announces Appointment of Tracey McCain as Chief Legal Officer and Executive Vice President
PR Newswire - Tue Sep 06, 3:01PM CDT
Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective investigational kinase medicines for patients with genomically defined diseases, today announced the appointment of Tracey McCain as Chief Legal Officer and Executive Vice President. Ms. McCain will be a member of the executive management team and will be responsible for all corporate legal operations for Blueprint Medicines.
BPMC: 29.17 (-0.10)
Why Blueprint Medicines (BPMC) Stock Might be a Great Pick
Zacks Equity Research - Zacks Investment Research - Tue Aug 16, 9:21AM CDT
Blueprint Medicines (BPMC) looks like an interesting choice for investors, as it is seeing solid estimate revisions and belongs to a great industry.
BPMC: 29.17 (-0.10)
Blueprint Medicines Reports Second Quarter 2016 Financial Results
PR Newswire - Tue Aug 09, 6:00AM CDT
Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today reported financial results and provided a business update for the second quarter ended June 30, 2016.
BPMC: 29.17 (-0.10)
Blueprint Medicines to Present at Upcoming Investor Conferences in August
PR Newswire - Wed Aug 03, 7:00AM CDT
Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today announced its participation in the following upcoming investor conferences:
BPMC: 29.17 (-0.10)
Blueprint Medicines to Report Second Quarter 2016 Financial Results on Tuesday, August 9, 2016
PR Newswire - Tue Aug 02, 7:00AM CDT
Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today announced that it will report second quarter 2016 financial results on Tuesday, August 9, 2016. Blueprint Medicines' management team will host a live conference call and audio webcast at 8:30 a.m. EDT on Tuesday, August 9, 2016 to discuss the financial results and provide a corporate update.
BPMC: 29.17 (-0.10)
Blueprint Medicines to Present at Upcoming Investor Conferences in June
PR Newswire - Wed Jun 01, 3:05PM CDT
Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today announced its participation in the following upcoming investor conferences:
BPMC: 29.17 (-0.10)
Blueprint Medicines reports 1Q loss
Automated Insights - Tue May 10, 6:26AM CDT
CAMBRIDGE, Mass. (AP) _ Blueprint Medicines Corp. (BPMC) on Tuesday reported a loss of $15.5 million in its first quarter.
BPMC: 29.17 (-0.10)
Blueprint Medicines Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 10, 6:00AM CDT
Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today reported financial results and provided a business update for the first quarter ended March 31, 2016.
BPMC: 29.17 (-0.10)
Blueprint Medicines to Report First Quarter 2016 Financial Results on Tuesday, May 10, 2016
PR Newswire - Tue May 03, 7:00AM CDT
Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today announced that it will report first quarter 2016 financial results on Tuesday, May 10, 2016. Blueprint Medicines' management team will host a live conference call and audio webcast at 8:00 a.m. EDT on Tuesday, May 10, 2016 to discuss the financial results and provide a corporate update.
BPMC: 29.17 (-0.10)
New Strong Buy Stocks for April 25th
Zacks Equity Research - Zacks Investment Research - Mon Apr 25, 8:15AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
BPMC: 29.17 (-0.10), BV: 5.00 (unch), ALGN: 95.34 (+1.64), BNFT: 38.43 (+0.65), BECN: 41.03 (+1.50)
Blueprint Medicines Appoints Lynn Seely, M.D. to Board of Directors
PR Newswire - Fri Apr 15, 7:00AM CDT
Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today announced the appointment of Lynn Seely, M.D. to its board of directors. Dr. Seely brings more than 20 years of cross-functional expertise within the healthcare industry, including experience in clinical and product development, business development and regulatory affairs.
BPMC: 29.17 (-0.10)
Global Liver Cancer Pipeline Review, H2 2015 - 150+ Companies & Drug Profiles
M2 - Tue Feb 09, 8:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/5j6swm/liver_cancer) has announced the addition of the "Liver Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Liver CancerOverview - Therapeutics Development - Pipeline Products for Liver Cancer- Overview - Pipeline Products for Liver Cancer- Comparative Analysis - Liver Cancer- Therapeutics under Development by Companies - Liver Cancer- Therapeutics under Investigation by Universities/Institutes - Liver Cancer- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Liver Cancer- Products under Development by Companies - Liver Cancer- Products under Investigation by Universities/Institutes - Liver Cancer- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 4SC AG - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - ACROVIS Pharma AG - Adaptimmune Limited - Aduro BioTech, Inc. - Advanced Accelerator Applications SA - Advenchen Laboratories, LLC - Alfact Innovation - Alnylam Pharmaceuticals, Inc. - American Gene Technologies International Inc. - Amgen Inc. - AndroScience Corporation - APAvadis Biotechnologies Srl - Arbutus Biopharma Corporation - ArQule, Inc. - Array BioPharma Inc. - Arrowhead Research Corporation - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bayer AG - Bio-Cancer Treatment International Limited - BioCancell Ltd - Biogazelle - Bioneer Corporation - BioStar Pharmaceuticals, Inc. - Blueprint Medicines - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - CASI Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/5j...ver_cancer
BPMC: 29.17 (-0.10), BSPM: 3.80 (unch), ADRO: 14.68 (+0.15), ARWR: 7.21 (-0.15), ARQL: 1.62 (+0.02), AMGN: 173.85 (+0.47), CASI: 1.05 (-0.02), BMY: 55.93 (+0.37), CLBS: 4.75 (+0.06), AAAP: 38.42 (-0.11), CANF: 2.62 (+0.10), ABUS: 3.89 (+0.05), AZN: 33.75 (+0.10), AVEO: 0.87 (unch), ABBV: 64.10 (+0.82), XLRN: 38.12 (+0.64), ARRY: 3.59 (-0.05)
Blueprint Medicines hires Lonnel Coats to board
M2 - Fri Feb 05, 3:01AM CST
Kinase medicines company Blueprint Medicines (NasdaqGS:BPMC) disclosed on Thursday the election of Lonnel Coats to its board of directors.
BPMC: 29.17 (-0.10), LXRX: 18.90 (-0.34)
Blueprint Medicines Appoints Lonnel Coats to Board of Directors
PR Newswire - Thu Feb 04, 3:05PM CST
Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective investigational kinase medicines for patients with genomically defined diseases, today announced the appointment to its board of directors of Lonnel Coats, a seasoned pharmaceutical executive with nearly 30 years of industry-related experience.
BPMC: 29.17 (-0.10), LXRX: 18.90 (-0.34)
(0)
(0)Scroll down for more posts ▼